JAGUAR HEALTH, INC. Payments of Stock Issuance Costs
JAGUAR HEALTH, INC. (JAGX) reported Payments of Stock Issuance Costs of $486.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2021-11-17
- JAGUAR HEALTH, INC. payments of stock issuance costs for the quarter ending 2021-09-30 was $0.00.
- JAGUAR HEALTH, INC. payments of stock issuance costs for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- JAGUAR HEALTH, INC. payments of stock issuance costs for the quarter ending 2015-09-30 was $21.76K, a 97.64% decline year-over-year.
- JAGUAR HEALTH, INC. payments of stock issuance costs for the quarter ending 2015-06-30 was $386.01K, a 53.20% decline year-over-year.
- JAGUAR HEALTH, INC. payments of stock issuance costs for fiscal 2019 was $65.00K, a 96.93% decline from fiscal 2018.
- JAGUAR HEALTH, INC. payments of stock issuance costs for fiscal 2018 was $2.12M.
- JAGUAR HEALTH, INC. payments of stock issuance costs for fiscal 2015 was $417.77K, a 83.15% decline from fiscal 2014.
- JAGUAR HEALTH, INC. payments of stock issuance costs for fiscal 2014 was $2.48M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 6 month as first filed | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-17 | $486.00K 10-Q · filed 2021-11-17 | |||
| 2021-06-30 | $486.00K 10-Q · filed 2021-08-13 | ||||
| 2020-06-30 | $13.00K 10-Q · filed 2021-08-13 | $51.00K 10-Q · filed 2020-08-13 | |||
| 2019-12-31 | $65.00K 10-K · filed 2021-03-31 | ||||
| 2019-06-30 | $3.00K 10-Q · filed 2020-08-13 | ||||
| 2018-12-31 | $2.12M 10-K · filed 2020-04-03 | ||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $21.76K derived: sum of 2 quarters · filed 2017-02-15 | $407.77K derived: sum of 3 quarters · filed 2017-02-15 | $417.77K 10-K · filed 2017-02-15 | |
| 2015-09-30 | $21.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $407.77K derived: sum of 2 quarters · filed 2016-11-14 | $417.77K 10-Q · filed 2016-11-14 | $943.82K derived: sum of 4 quarters · filed 2016-11-14 | |
| 2015-06-30 | $386.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $396.01K 10-Q · filed 2016-08-15 | $922.05K derived: sum of 3 quarters · filed 2016-08-15 | $1.85M derived: sum of 4 quarters · filed 2016-08-15 | |
| 2015-03-31 | $10.00K 10-Q · filed 2016-05-10 | $536.04K derived: sum of 2 quarters · filed 2016-05-10 | $1.46M derived: sum of 3 quarters · filed 2016-05-10 | $2.28M derived: sum of 4 quarters · filed 2016-05-10 | |
| 2014-12-31 | $526.04K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | $1.45M derived: sum of 2 quarters · filed 2016-03-29 | $2.27M derived: sum of 3 quarters · filed 2016-03-29 | $2.48M 10-K · filed 2016-03-29 | |
| 2014-09-30 | $924.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $1.75M derived: sum of 2 quarters · filed 2015-11-13 | $1.95M 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | $824.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $1.03M 10-Q · filed 2015-08-13 | |||
| 2014-03-31 | $205.07K 10-Q · filed 2015-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |